ACR (American College of Rheumatology) is a society covering all immune-related diseases, and cette année's conference is scheduled to be held at the San Diego Convention Center from November 10 to 15.
This présentation de poster will feature résultats précliniques for an arthrose pain-inhibiting compound, part of RudaCure's RCI002 project actuellement under development. The results to be presented demonstrate pain suppression for up to two weeks following a single administration.
Through formulation research, this compound devrait be applicable not only for arthrose but also for degenerative disc disease (cervical and lumbar spine, etc.) with administration once every six months or once a year.
